Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has been selected to present at BIO-Europe, a leading European pharmaceutical-biotechnology conference. The CEO of Motif, Graham Lumsden, will present.
Presentation dates:
The BIO-Europe 2015 conference on November 2 through November 4, 2015 at the International Congress Center (ICM) in Munich, Germany. Motif will be presenting at 16:45 CET on November 3 in Room 2, Level 0.
Enquiries
Motif Bio plc
Graham Lumsden, Chief Executive Officer
David Huang, Chief Medical Officer
[email protected]
Zeus Capital Limited (Nominated Advisor and Broker)
Phil Walker / Dan Bate
Dominic Wilson
+44 (0) 20 3829 5000
Northland Capital Partners (Broker)
Patrick Claridge / David Hignell
John Howes / Mark Treharne (Broking)
+44 (0) 207 382 1100
MC Services AG (Trade PR)
Raimund Gabriel
Shaun Brown
+49 (0) 89 210 2280
+44 (0) 207 148 5998
Plumtree Capital Limited (Financial Advisor)
Stephen Austin
+44 (0) 207 183 2493
Yellow Jersey PR (Financial PR)
Charles Goodwin
Dominic Barretto
+44 (0) 7747 788 221
Notes to Editors
Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.
Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.
The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.